Content
07/31/2024
Cambridge, MA USA
AIRNA
completed $90 million Series A Round funding. Investors include
Forbion Capital Partners (lead), Alexandria Venture Investments, ARCH Venture Partners, +ND Capital, Ono Venture Investment.
About
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
